Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (701)	6/25/2001 8:54:55 PM
From: tuck	Respond to of 1784

Wilder, We have made a gracious team effort, starting with yours. Enjoy the movie. You have said MDZ wasn't as overpriced as the other trickle companies, but Trickle and I, and perhaps Rick, have already acted on that one, too. Next, please. Haven't looked in on little EBIO in a while. Thinking it might be a cheap way to play an ABI rebound? It's just been basing for sooo long. >>BOTHELL, Wash., Jun 25, 2001 /PRNewswire via COMTEX/ -- Epoch Biosciences, Inc. (Nasdaq: EBIO chart, msgs), a leading provider of proprietary chemistries and reagents that enable genomics research, announced today that it has licensed technology from Applied Biosystems (NYSE: ABI chart, msgs), an Applera Corporation business, relating to hybridization assays using non-cleavable fluorescent self-quenching probes. Epoch is currently developing gene expression and single nucleotide polymorphism (SNP) assays that employ its proprietary technologies, including the Minor Groove Binder (MGB), modified bases, Eclipse(TM) Quencher, and novel fluorescent dyes. Epoch's Eclipse(TM) probe assays, scheduled for release this summer, will allow affordable, reproducible and sensitive measurement of gene expression and detection of genetic polymorphisms for academic, biotech, diagnostic and pharmaceutical researchers. The Eclipse(TM) probes will be the first proprietary product that Epoch will introduce to the commercial marketplace. The Eclipse(TM) probes incorporate all the advantages of Epoch's technology. The MGB component improves discrimination in SNP genotyping experiments and ensures robust sequence detection. Epoch's modified nucleosides expand the utility of DNA probes and afford homogenous detection at a uniform temperature. In addition, Epoch's proprietary dyes and quencher allow a broad range of detection systems to be used and afford multiplex detection for high throughput analysis. William G. Gerber, M.D., chief executive officer of Epoch, commented, "Epoch is expanding its business model beyond licensing of our proprietary technologies to include manufacturing and direct sales of our own value-added products. The licensing agreement with Applied Biosystems is a key step towards the release of our Eclipse(TM) probe line, which we believe will be an important alternative for genomic researchers interested in highly reliable and highly sensitive DNA detection and discrimination systems." "We are pleased to provide our probe technology to Epoch Biosciences as they near the release of their Eclipse(TM) probe line," said Michael Y. Lucero, vice president of Applications Marketing and R&D at Applied Biosystems.<< snip Cheers, Tuck